Sartorius exhibit vivifying stock figures prior to stock devaluation
Sartorius AG, a leading laboratory equipment manufacturer based in Göttingen, Germany, has made a significant investment in the production of transfection reagents for pharmaceutical quality. The expansion, which took place at a site in Illkirch near Strasbourg, France, underscores Sartorius' ambition to support customers in the development and production of cell and gene therapies.
René Fabré, a member of Sartorius' board and CEO of the subsidiary Sartorius Stedim Biotech, stated that the expanded site in Illkirch will better support Sartorius' customers. This expansion comes at a time when the field of cell and gene therapies is experiencing massive growth.
The production facility in Illkirch is state-of-the-art and capable of manufacturing transfection reagents in pharmaceutical quality (GMP). Sartorius has also selected Göttingen (Germany), Irvine (USA), and Suzhou (China) as additional production sites for manufacturing transfection reagents in pharmaceutical quality.
The expansion is intended to help Sartorius' customers bring innovative therapies to patients faster and more efficiently. Sartorius' investment story remains attractive, with a P/E ratio of around 40 for 2026. Despite being heavily discounted, Sartorius shares are still sportily valued.
The approval of the world's first CAR-T cell therapy, Kymriah, by Novartis in August 2017, marked a significant milestone in the cell and gene therapy industry. Since then, more and more treatment options for cell and gene therapies have entered the market or are about to enter it.
As investors wait for positive chart signals for Sartorius shares, the company is preparing for increasing demand for next-generation technologies for cell and gene therapies. The expanded site in Illkirch will serve as a central production facility within Sartorius' global network, further solidifying its position in the dynamically growing segment of biopharmaceuticals.
Sartorius shares have recently exceeded the 200 euros mark, and the company is expected to leave the DAX soon. Despite this, Sartorius remains committed to its mission of supporting the biopharmaceutical industry in its quest to develop and produce innovative therapies for patients.
